Unicycive Therapeutics, Inc.

On August 13, 2025, we filed a Certificate of Correction with the Secretary of State of Delaware (“Certificate of Correction”) for our Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Voting Preferred Stock (“Series A Certificate of Designation”) filed with the Secretary of State of Delaware on March 13, 2024. The Certificate of Correction was filed to correct certain scrivener’s errors in the Series A Certificate of Designation with respect to adjustments for stock dividends and stock splits under Section 7(a) of the Series A Certificate of Designation which inadvertently stated that the Conversion Price for each series of Series A Preferred Stock adjusted upon any stock dividends and stock splits if such actions occurred at any time when any shares of Series A Preferred Stock were outstanding whereas there should only be an adjustment to the Conversion Price of a particular series of Series A Preferred Stock for any shares of such series of Series A Preferred Stock outstanding at the time of the stock dividend or stock split. Pursuant to Section 103(f) of the Delaware General Corporation Law, the correction was effective as of March 14, 2024, except as to those persons who are substantially and adversely affected by the correction, and as to those persons the correction was effective as of August 13, 2025.

The foregoing description of the Certificate of Correction is qualified in its entirety by reference to the full text of the Certificate of Correction, which is filed herewith as Exhibit 3.1 and incorporated herein by reference.